Angiology

InspireMD Announces Warrants Exchange Listing Transfer to Nasdaq

Retrieved on: 
Thursday, May 27, 2021
Medical specialties, Angiology, Vascular diseases, Cardiovascular system, Neurosurgery, Vascular surgery, Carotid artery stenosis, Carotid stenting, Stroke, Carotid artery, NASDAQ

TEL AVIV, Israel, May 27, 2021 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of Carotid Artery Disease (CAD), today announced the Companys warrants, NSPR.WS and NSPR.WSB, currently traded on the NYSE: American, have been approved for listing on The Nasdaq Capital Market (Nasdaq).

Key Points: 
  • TEL AVIV, Israel, May 27, 2021 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of Carotid Artery Disease (CAD), today announced the Companys warrants, NSPR.WS and NSPR.WSB, currently traded on the NYSE: American, have been approved for listing on The Nasdaq Capital Market (Nasdaq).
  • Trading is expected to begin onJune 8, 2021, under the symbols NSPRW and NSPRZ on the Nasdaq.
  • InspireMD seeks to utilize its proprietary MicroNet technology to make its products the industry standard for carotid stenting by providing outstanding acute results and durable, stroke-free, long-term outcomes.
  • Investors and security holders are urged to read these documents free of charge on the SECs web site at http://www.sec.gov.

Upper East Side Cardiology Launches New Vein Institute as Extension to Personalized Patient Services

Retrieved on: 
Monday, May 24, 2021
Angiology, Medical specialties, Cardiovascular system, Veins, Vascular surgery, Varicose veins

NEW YORK, May 24, 2021 /PRNewswire/ --One of New York City's leading cardiac treatment centers, Upper East Side Cardiology , led by Satjit Bhusri, MD, FACC, announced today the launch of The Vein Institute - The Premier Varicose Vein Treatment Center on the Upper East Side.

Key Points: 
  • NEW YORK, May 24, 2021 /PRNewswire/ --One of New York City's leading cardiac treatment centers, Upper East Side Cardiology , led by Satjit Bhusri, MD, FACC, announced today the launch of The Vein Institute - The Premier Varicose Vein Treatment Center on the Upper East Side.
  • That's why The Vein Institute is so dedicated to creating customized treatment plans for our patients to restore both their vascular health and comfort."
  • The Vein Institute at Upper East Side Cardiology offers several, personalized treatment options for varicose veins, most of which are covered by insurance including:
    VenaSeal an advanced technique that quickly and safely eliminates the veins using a specially formulated adhesive.
  • Dr. Bhusri is one of the only physicians on the Upper East Side to utilize this leading technology for the treatment of varicose veins.

Koya Medical to Present at Oppenheimer MedTech, Tools & Diagnostics Summit

Retrieved on: 
Thursday, May 20, 2021
Branches of biology, Angiology, Medical specialties, Lymphedema, Medtech, Vein, Edema

b"OAKLAND, Calif., May 20, 2021 /PRNewswire/ -- Koya Medical , a healthcare company focused on developing breakthrough treatments for lymphedema and venous diseases, will present at the Oppenheimer MedTech, Tools & Diagnostics Summit on Wednesday, May 26, 2021.

Key Points: 
  • b"OAKLAND, Calif., May 20, 2021 /PRNewswire/ -- Koya Medical , a healthcare company focused on developing breakthrough treatments for lymphedema and venous diseases, will present at the Oppenheimer MedTech, Tools & Diagnostics Summit on Wednesday, May 26, 2021.
  • The Company's presentation will be available throughout the day on May 26 to all conference participants.\nThe Oppenheimer MedTech, Tools & Diagnostics Summit investor conference will be held virtually.
  • The privately held company was founded in 2018 with the mission to transform lymphatic and vein care through innovative patient-centric platforms.
  • It is the first and only compression therapy option designed to enable movement, mobility and personalized care that is unavailable with traditional compression therapy.

Acceleron Presents Interim Results from the Open-label Extension of the PULSAR Phase 2 Trial of Sotatercept in Patients with Pulmonary Arterial Hypertension (PAH) at the American Thoracic Society 2021 International Conference

Retrieved on: 
Wednesday, May 19, 2021
Biotechnology, Health, Pharmaceutical, Clinical trials, Cardiology, Cardiovascular system, Circulatory system, Medicine, Angiology, Hypertension, Pulmonary hypertension, Vascular resistance, Cardiac catheterization, PVR, Pulmonary artery catheter, Blood vessel, Persistent fetal circulation, the PULSAR Trial, Sotatercept, PAH, Acceleron, THE PULSAR TRIAL, SOTATERCEPT, PAH, ACCELERON

We look forward to collecting additional, potentially confirmatory data through this ongoing open-label extension study and in the next phase of clinical development.\xe2\x80\x9d\nSotatercept was generally well tolerated in the trial.

Key Points: 
  • We look forward to collecting additional, potentially confirmatory data through this ongoing open-label extension study and in the next phase of clinical development.\xe2\x80\x9d\nSotatercept was generally well tolerated in the trial.
  • The primary endpoint of the trial was the change from baseline in pulmonary vascular resistance (PVR) over a 24-week treatment period.
  • PVR, as measured by right heart catheterization, is the resistance that the heart must overcome to pump blood through the pulmonary circulatory system.
  • In pulmonary, Acceleron is developing sotatercept for the treatment of pulmonary arterial hypertension (PAH), having reported positive topline results of the PULSAR Phase 2 trial.

OncXerna Therapeutics to Present at Jefferies Virtual Healthcare Conference

Retrieved on: 
Tuesday, May 18, 2021
Branches of biology, Angiology, Medical specialties, Clinical medicine, Growth factors, Vascular endothelial growth factor, Angiogenesis, Checkpoint inhibitor, Bavituximab

b'WALTHAM, Mass., May 18, 2021 (GLOBE NEWSWIRE) -- OncXerna Therapeutics, Inc., a precision medicine company using an innovative RNA-expression based biomarker platform to predict patient responses to its first-in-class targeted oncology therapies, today announced that Laura Benjamin, Ph.D., Founder and CEO of OncXerna, will present at the Jefferies Virtual Healthcare Conference taking place June 1-4, 2021.\nThe live presentation will occur on June 4, 2021 from 10:30 a.m. to 10:55 a.m.

Key Points: 
  • b'WALTHAM, Mass., May 18, 2021 (GLOBE NEWSWIRE) -- OncXerna Therapeutics, Inc., a precision medicine company using an innovative RNA-expression based biomarker platform to predict patient responses to its first-in-class targeted oncology therapies, today announced that Laura Benjamin, Ph.D., Founder and CEO of OncXerna, will present at the Jefferies Virtual Healthcare Conference taking place June 1-4, 2021.\nThe live presentation will occur on June 4, 2021 from 10:30 a.m. to 10:55 a.m.
  • This allows OncXerna to pair those patients with OncXerna\xe2\x80\x99s clinical-stage therapies and known mechanism of action that directly address these biologies, to dramatically improve patient outcomes.
  • OncXerna is targeting patients whose dominant tumor biology is driven by angiogenesis with a focus beyond VEGF to include broader anti-angiogenic pathways.
  • OncXerna\xe2\x80\x99s clinical trials currently combine bavituximab with KEYTRUDA\xc2\xae to test the hypothesis that relieving immunosuppression can enhance responses to checkpoint inhibitors.

Arctic Vision announces exclusive licensing agreement with ActualEyes

Retrieved on: 
Friday, May 14, 2021
Angiology, Endothelium, Endothelial dysfunction, Medical specialties, Organ systems, Clinical medicine

Studies[i],[ii] have demonstrated that the injection of hCECs supplemented with a ROCK inhibitor has positive efficacy and safety profiles in patients with corneal endothelial dysfunction.

Key Points: 
  • Studies[i],[ii] have demonstrated that the injection of hCECs supplemented with a ROCK inhibitor has positive efficacy and safety profiles in patients with corneal endothelial dysfunction.
  • Eddy (Hoi Ti) Wu, Founder and CEO, Board Director of Arctic Vision, commented, "We are excited to enter into this partnership with ActualEyes to further develop AE-101, a potent cell-therapy solution for the treatment of corneal endothelial dysfunction.
  • "\nIku Sugioka, President and Chief Executive Officer of ActualEyes, said, "We look forward to collaborating with Arctic Vision to develop our lead clinical candidate AE-101.
  • The company\'s vision is to address ophthalmology\'s unmet needs through innovative therapies in China, Asia and globally.

4D Molecular Therapeutics Presents Non-Human Primate Preclinical Data at ASGCT on the 4D-150 Product Candidate for wet AMD and DME

Retrieved on: 
Wednesday, May 12, 2021
Branches of biology, Clinical medicine, Ophthalmology, Angiology, Vascular endothelial growth factor, Intravitreal administration, Macular degeneration, Angiogenesis, Retina, Angiogenesis inhibitor

The proliferation of abnormal blood vessels in the retina is stimulated by VEGF.

Key Points: 
  • The proliferation of abnormal blood vessels in the retina is stimulated by VEGF.
  • There are on average 200,000 new incidences of wet AMD per year in the United States alone.
  • The prevalence of DME is high, affecting approximately 1.1 million adults in the United States.\n4D-150 is designed as a dual transgene, intravitreal gene therapy inhibiting four distinct VEGF family members to prevent angiogenesis for the treatment of wet AMD and DME.
  • No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.\n'

aTyr Pharma and its Hong Kong Subsidiary, Pangu BioPharma, Achieve Milestones for First Year of Government Grant to Develop Bispecific Antibody Platform

Retrieved on: 
Wednesday, May 12, 2021
Branches of biology, Medical specialties, Cytokines, Chemokine receptors, Clusters of differentiation, C-C chemokine receptor type 7, CCL21, Angiology, Dendritic cell, Neuropilin 2, Forward-looking statement, Lymphatic system

\xe2\x80\x9cWe continue to learn more about NRP2 as a target for diseases, including immunology and cancer.

Key Points: 
  • \xe2\x80\x9cWe continue to learn more about NRP2 as a target for diseases, including immunology and cancer.
  • In addition, NRP2 modulates interactions between CCL21 and CCR7 potentially impacting homing of dendritic cells to lymphoid organs.
  • All forward-looking statements are based on estimates and assumptions by our management that, although we believe to be reasonable, are inherently uncertain.
  • Except as required by law, we assume no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.\n'

Ocugen Presents New Preclinical OCU200 Data at the Association for Research in Vision and Ophthalmology (ARVO) 2021 Annual Meeting

Retrieved on: 
Thursday, May 6, 2021
Angiology, Branches of biology, Medical specialties, Vascular endothelial growth factor, Angiogenesis, Endothelium, Angiogenesis inhibitor, Anti–vascular endothelial growth factor therapy

The purpose of this study was to evaluate efficacy of OCU200 in in-vitro and in-vivo models for ocular neovascular diseases.

Key Points: 
  • The purpose of this study was to evaluate efficacy of OCU200 in in-vitro and in-vivo models for ocular neovascular diseases.
  • Most approved therapeutics target vascular endothelial growth factor (VEGF), a pro-angiogenic factor with neurotrophic and neuroprotective effects.
  • However, approximately 50% of Patients do not respond to anti-VEGF/Corticosteroids therapies.\nOCU200 inhibited cell proliferation, cell invasion and tube formation by endothelial cells.
  • Arun Upadhyay, VP and Head of R&D, Ocugen Inc.\n'

FDA Approves Orgenesis IDE for Pilot Clinical Trial of its Tissue Genesis Icellator2® to Treat ARDS Resulting from COVID-19 Infection

Retrieved on: 
Thursday, May 6, 2021
Branches of biology, Biology, Life sciences, Stem cells, Angiology, Biotechnology, Cell biology, Acute respiratory distress syndrome, Intensive care medicine, Endothelium, Mesenchymal stem cell

The SVF derived from the Icellator2 contains a population of mesenchymal stem cells, vascular endothelial cells, and immune cells which migrate to the patient\xe2\x80\x99s lungs and other peripheral sites of inflammation.

Key Points: 
  • The SVF derived from the Icellator2 contains a population of mesenchymal stem cells, vascular endothelial cells, and immune cells which migrate to the patient\xe2\x80\x99s lungs and other peripheral sites of inflammation.
  • Orgenesis believes the multiple mechanisms of action of the SVF derived from the Icellator2 are important to treat ARDS and other inflammatory disorders.\nThe FDA IDE approval covers 21 patients at one clinical site in the United States.
  • We are excited to move forward with clinical development of the Icellator to treat ARDS, COVID-19-related complications, and other serious conditions.
  • Our interactions with the FDA through the IDE process will inform our development plans.